Keep Your Knowledge Current! – New Guidelines for Prostate Cancer Screening
Florida Hospital Cancer Institute has released new recommendations for prostate cancer screening.
In line with the efforts of the International Prostate Cancer Foundation, the FHCI is dedicated to providing patients with the latest treatments and technologies, managed by an experienced, knowledgeable team that focuses on delivering patients the most positive outcomes possible.
As the largest cancer center in Central Florida, recognized worldwide for its comprehensive, state-of-the-art care and reputation as a destination cancer care facility… their expertise should not go ignored!
Florida Hospital Cancer Institute Recommendations for Prostate Cancer Screening*
- At age 40 men with greater than 10-15 year life expectancy should be risk stratified and considered for Prostate Cancer Screening.
- Doctors should start conversing with men about the potential benefits, uncertainties, and risks of Prostate Cancer Screening in the following risk categories:
- Very high risk – (men with more than one first degree relative) begin the conversation at age 40.
- High risk – (men of African American descent and/or those who have a single first degree relative – father, brother or son diagnosed with prostate cancer before age 65) begin the conversation at age 45.
- Average risk – begin conversation at age 50.
- Screening should include the PSA blood test and Digital Rectal Exam.
- Men with less than 10-15 year life expectancy should not be offered Prostate Cancer Screening.
The exact interval (yearly, biennial, or every 4 years) of subsequent Prostate Cancer Screenings are still uncertain and the pros and cons of future screening intervals should be discussed with each patient.
*These recommendations are adopted based upon the guidance of our FHCI expert panel and with consideration of the American Cancer Society Recommendations on Prostate Cancer Screening and the American Urological Association (AUA) Guideline.
Ranked among the top five in the nation for robotic gynecologic-oncology surgeries and the world leader in robotic prostatectomies using the da Vinci® Surgical System, the FHCI performs more than 8,000 cancer surgeries performed annually.
The Florida Hospital Cancer Institute is accredited as a Community Comprehensive Cancer Center by the American College of Surgeons Commission on Cancer and is recognized by the American Society of Clinical Oncology for its clinical research. They strive and succeed in maintaining research affiliations with the National Cancer Institute, Sarah Cannon Research Institute and many other health care institutions and organizations.
For more information on the FHCI we invite you to visit their website: https://www.floridahospitalcancer.com/about-us